A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING SINGLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AMG 529, A NOVEL ANTI-ASGR1 MONOCLONAL ANTIBODY, IN HEALTHY SUBJECTS

Heterozygous carriers of a rare 12-base-pair deletion (del12), loss-of-function variant in the asialoglycoprotein receptor (ASGPR) subunit 1 ( ASGR1 ) had lower levels of non-high-density lipoprotein cholesterol, reduced risk for myocardial infarction and coronary artery disease, and increased